These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23565287)

  • 1. Ghrelin-induced orexigenic effect in rats depends on the metabolic status and is counteracted by peripheral CB1 receptor antagonism.
    Alen F; Crespo I; Ramírez-López MT; Jagerovic N; Goya P; de Fonseca FR; de Heras RG; Orio L
    PLoS One; 2013; 8(4):e60918. PubMed ID: 23565287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential modulation of endogenous cannabinoid CB1 and CB2 receptors in spontaneous and splice variants of ghrelin-induced food intake in conscious rats.
    Ting CH; Chi CW; Li CP; Chen CY
    Nutrition; 2015 Jan; 31(1):230-5. PubMed ID: 25466669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system.
    Kola B; Farkas I; Christ-Crain M; Wittmann G; Lolli F; Amin F; Harvey-White J; Liposits Z; Kunos G; Grossman AB; Fekete C; Korbonits M
    PLoS One; 2008 Mar; 3(3):e1797. PubMed ID: 18335063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gastric CB1 receptor modulates ghrelin production through the mTOR pathway to regulate food intake.
    Senin LL; Al-Massadi O; Folgueira C; Castelao C; Pardo M; Barja-Fernandez S; Roca-Rivada A; Amil M; Crujeiras AB; Garcia-Caballero T; Gabellieri E; Leis R; Dieguez C; Pagotto U; Casanueva FF; Seoane LM
    PLoS One; 2013; 8(11):e80339. PubMed ID: 24303008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
    Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
    J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin.
    Tucci SA; Rogers EK; Korbonits M; Kirkham TC
    Br J Pharmacol; 2004 Nov; 143(5):520-3. PubMed ID: 15381634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide.
    Cani PD; Montoya ML; Neyrinck AM; Delzenne NM; Lambert DM
    Br J Nutr; 2004 Nov; 92(5):757-61. PubMed ID: 15533263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.
    Gómez R; Navarro M; Ferrer B; Trigo JM; Bilbao A; Del Arco I; Cippitelli A; Nava F; Piomelli D; Rodríguez de Fonseca F
    J Neurosci; 2002 Nov; 22(21):9612-7. PubMed ID: 12417686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats.
    Ward SJ; Lefever TW; Rawls SM; Whiteside GT; Walker EA
    Psychopharmacology (Berl); 2009 Sep; 206(1):155-65. PubMed ID: 19575185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoid type-1 receptors in the paraventricular nucleus of the hypothalamus inhibit stimulated food intake.
    Soria-Gómez E; Massa F; Bellocchio L; Rueda-Orozco PE; Ciofi P; Cota D; Oliet SH; Prospéro-García O; Marsicano G
    Neuroscience; 2014 Mar; 263():46-53. PubMed ID: 24434770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral endocannabinoid system-mediated actions of rimonabant on growth hormone secretion are ghrelin-dependent.
    Al-Massadi O; Gabellieri E; Trujillo ML; Señaris R; Pagotto U; Pasquali R; Casanueva FF; Seoane LM
    J Neuroendocrinol; 2010 Nov; 22(11):1127-36. PubMed ID: 20807320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release.
    Kola B; Wittman G; Bodnár I; Amin F; Lim CT; Oláh M; Christ-Crain M; Lolli F; van Thuijl H; Leontiou CA; Füzesi T; Dalino P; Isidori AM; Harvey-White J; Kunos G; Nagy GM; Grossman AB; Fekete C; Korbonits M
    FASEB J; 2013 Dec; 27(12):5112-21. PubMed ID: 23982145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1.
    Crespo I; Gómez de Heras R; Rodríguez de Fonseca F; Navarro M
    Neuropharmacology; 2008 Jan; 54(1):219-25. PubMed ID: 17889909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ghrelin-Ghrelin receptor (GSHR) pathway via endocannabinoid signal affects the expression of NPY to promote the food intake of Siberian sturgeon (Acipenser baerii).
    Chen D; Li Y; Wu H; Wu Y; Tang N; Chen S; Liu Y; Wang J; Zhang X; Li Z
    Horm Behav; 2022 Jul; 143():105199. PubMed ID: 35597053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
    Serrano A; Del Arco I; Javier Pavón F; Macías M; Perez-Valero V; Rodríguez de Fonseca F
    Neuropharmacology; 2008 Jan; 54(1):226-34. PubMed ID: 17467748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerance to hypophagia induced by prolonged treatment with a CB1 antagonist is related to the reversion of anorexigenic neuropeptide gene expression in the hypothalamus.
    Rorato R; Miyahara C; Antunes-Rodrigues J; Elias LL
    Regul Pept; 2013 Mar; 182():12-8. PubMed ID: 23327999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats.
    Järbe TU; DiPatrizio NV
    Behav Pharmacol; 2005 Sep; 16(5-6):373-80. PubMed ID: 16148441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats.
    Bennetzen MF; Nielsen MP; Richelsen B; Pedersen SB
    Obesity (Silver Spring); 2008 Nov; 16(11):2451-5. PubMed ID: 18719671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.
    Nogueiras R; Veyrat-Durebex C; Suchanek PM; Klein M; Tschöp J; Caldwell C; Woods SC; Wittmann G; Watanabe M; Liposits Z; Fekete C; Reizes O; Rohner-Jeanrenaud F; Tschöp MH
    Diabetes; 2008 Nov; 57(11):2977-91. PubMed ID: 18716045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early tolerance to the hypophagic effect of the cannabinoid receptor antagonist SR141716 does not impede blockade of an orexigenic stimulus.
    Rigamonti AE; Giordani C; Bonomo SM; Cella SG; Müller EE
    Eur J Pharmacol; 2006 Aug; 542(1-3):116-20. PubMed ID: 16806163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.